Early Access — free while we kick the tires
EdgarHawk

Nunn Jason Raleigh

Director

Director
2 filings analyzed · 1 company · Latest 2025-10-14

Companies

Company Buys Sells Direction
Zenas BioPharma, Inc. ZBIO 5 0 Net buying

Activity

October 2025
2025-10-14 Zenas BioPharma, Inc. ZBIO
medium
Buy
63,158 shares
$1,200,002
Significance 5/10

Director Jason Raleigh Nunn purchases 63,158 shares of ZBIO at $19.00 ($1.2M); stock now $25.85; 5 insiders bought in past 14 days

Jason Raleigh Nunn, a Director, purchased 63,158 shares at $19.00 on 2025-10-09, increasing his holdings to 1,173,395 shares (a 5.7% increase). The stock has appreciated to $25.85, representing a +27.8% gain over the prior 30 days and a +97.8% gain over the prior 90 days. However, this positive near-term price action must be contextualized against both the insider's track record and the company's fundamentals. His prior 2 open-market buys across all tickers averaged a 90-day return of -47.5%, with a 0.00% win rate at the 90-day mark; his same-ticker history at ZBIO (2 prior buys on 2024-09-16) shows identical 90-day results of -47.5%. Additionally, the company is unprofitable (net income of -$52,223,000.00), reported zero revenue in its latest quarter, and experienced -90.0% annual revenue decline year-over-year, creating a significant fundamental headwind despite the recent stock momentum. A cluster of 5 other insiders also buying within the past 14 days suggests coordinated interest, though this does not alter the underlying operational challenges evident in the financials.

September 2024
2024-09-16 Zenas BioPharma, Inc. ZBIO
high
Buy
882,352 shares
$14,999,984
Significance 7/10

Director Jason Raleigh Nunn purchases 882,352 shares at $17.00 in 2 transactions; 5 other insiders bought within 14 days

Director Jason Raleigh Nunn executed 2 separate purchases totaling 882,352 shares for $14,999,984.00 on 2024-09-16, the same day ZBIO's IPO priced at $17.00 (current price is $17.97). His post-transaction holdings of 1,110,237 shares represent a +387.2% increase from his pre-transaction position of 227,885 shares, indicating a substantial commitment during the company's newly public phase. The CLUSTER pattern shows 5 other insiders also bought within the past 14 days, reflecting broad insider participation at or near the IPO price point. This filing documents participation in an IPO allocation rather than a discretionary open-market conviction signal, but the scale of Nunn's commitment and the synchronized multi-insider buying activity warrant investor attention during this critical early trading period.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access